ANRO
Alto Neuroscience, Inc.
Biotechnology
Market Cap$753M
5Y Perf.+39.4%
Build Your Comparison
Side-by-side financial analysisANRO
SAVA
Try popular comparisons:
Stock Comparison
ANRO vs SAVA
Revenue, margins, valuation, and 5-year total return — side by side.
SAVA
Cassava Sciences, Inc.
Biotechnology
Market Cap$64M
5Y Perf.-30.5%
ANRO vs SAVA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  ANRO |  SAVA |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $753M | $64M |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-74M | $-106M |
| Total Debt | $4M | $0.00 |
| Cash & Equiv. | $176M | $129M |
ANRO vs SAVA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ANRO
SAVA
| Stock | Feb 24 | Jun 26 | Return |
|---|---|---|---|
| Alto Neuroscience, … (ANRO) | 100 | 139.4 | +39.4% |
| Cassava Sciences, I… (SAVA) | 100 | 69.5 | -30.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ANRO vs SAVA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ANRO leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and recent price momentum and sentiment. Cassava Sciences, Inc. is the stronger pick specifically for profitability and margin quality and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
🥇ANRO emerged as the overall leader. Track its performance:
ANRO
Alto Neuroscience, Inc.
The Long-Run Compounder
ANRO carries the broadest edge in this set and is the clearest fit for long-term compounding.
- 3.7% 10Y total return vs SAVA's -38.0%
- -17.7% revenue growth vs SAVA's -5.4%
- +7.8% vs SAVA's -37.7%
Best for: long-term compounding
SAVA
Cassava Sciences, Inc.
The Income Pick
SAVA is the clearest fit if your priority is income & stability and growth exposure.
- Dividend streak 0 yrs, beta 1.92
- EPS growth 77.6%
- Lower volatility, beta 1.92, current ratio 11.62x
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  ANRO | -17.7% revenue growth vs SAVA's -5.4% |
| Quality / Margins |  SAVA | 5.4% margin vs ANRO's 2.2% |
| Stability / Safety | SAVA | Beta 1.92 vs ANRO's 2.60 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ANRO | +7.8% vs SAVA's -37.7% |
| Efficiency (ROA) | ANRO | -38.8% ROA vs SAVA's -75.3% |
ANRO vs SAVA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLANROLAGGINGSAVA
SAVACassava Sciences, Inc.
1leads
ANROAlto Neuroscience, In…
2leads
6 Total Categories
CATEGORYLEADERvs SAVAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
SAVA1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ANRO5/6
Total Returns1Y, 3Y, 5Y total returns with dividends
ANRO6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
SAVA leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ANRO and SAVA operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | ANROAlto Neuroscience… | SAVACassava Sciences,… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | $56M | -$110M |
| Net IncomeAfter-tax profit | -$74M | -$106M |
| Free Cash FlowCash after capex | -$63M | -$84M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -42.9% | +62.1% |
SAVA leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — ANRO and SAVA each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | ANROAlto Neuroscience… | SAVACassava Sciences,… |
|---|---|---|
| Market CapShares × price | $753M | $64M |
| Enterprise ValueMkt cap + debt − cash | $581M | -$65M |
| Trailing P/EPrice ÷ TTM EPS | -9.80x | -2.54x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 4.10x | 0.42x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — ANRO and SAVA each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
ANRO leads this category, winning 5 of 6 comparable metrics.
Profitability & Efficiency
ANRO delivers a -47.2% return on equity — every $100 of shareholder capital generates $-47 in annual profit, vs $-96 for SAVA. On the Piotroski fundamental quality scale (0–9), ANRO scores 3/9 vs SAVA's 2/9, reflecting mixed financial health.
| Metric | ANROAlto Neuroscience… | SAVACassava Sciences,… |
|---|---|---|
| ROE (TTM)Return on equity | -47.2% | -95.8% |
| ROA (TTM)Return on assets | -38.8% | -75.3% |
| ROICReturn on invested capital | — | -6.3% |
| ROCEReturn on capital employed | -38.9% | -99.9% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 2 |
| Debt / EquityFinancial leverage | 0.03x | — |
| Net DebtTotal debt minus cash | -$172M | -$129M |
| Cash & Equiv.Liquid assets | $176M | $129M |
| Total DebtShort + long-term debt | $4M | $0 |
| Interest CoverageEBIT ÷ Interest expense | -30.35x | — |
ANRO leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
ANRO leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ANRO five years ago would be worth $10,372 today (with dividends reinvested), compared to $1,219 for SAVA. Over the past 12 months, ANRO leads with a +776.3% total return vs SAVA's -37.7%. The 3-year compound annual growth rate (CAGR) favors ANRO at 1.2% vs SAVA's -27.9% — a key indicator of consistent wealth creation.
| Metric | ANROAlto Neuroscience… | SAVACassava Sciences,… |
|---|---|---|
| YTD ReturnYear-to-date | +29.4% | -36.8% |
| 1-Year ReturnPast 12 months | +776.3% | -37.7% |
| 3-Year ReturnCumulative with dividends | +3.7% | -62.5% |
| 5-Year ReturnCumulative with dividends | +3.7% | -87.8% |
| 10-Year ReturnCumulative with dividends | +3.7% | -38.0% |
| CAGR (3Y)Annualised 3-year return | +1.2% | -27.9% |
ANRO leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — ANRO and SAVA each lead in 1 of 2 comparable metrics.
Risk & Volatility
SAVA is the less volatile stock with a 1.92 beta — it tends to amplify market swings less than ANRO's 2.60 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ANRO currently trades 75.5% from its 52-week high vs SAVA's 26.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ANROAlto Neuroscience… | SAVACassava Sciences,… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.60x | 1.92x |
| 52-Week HighHighest price in past year | $28.44 | $4.98 |
| 52-Week LowLowest price in past year | $2.15 | $1.27 |
| % of 52W HighCurrent price vs 52-week peak | +75.5% | +26.5% |
| RSI (14)Momentum oscillator 0–100 | 51.3 | 42.7 |
| Avg Volume (50D)Average daily shares traded | 316K | 134K |
Evenly matched — ANRO and SAVA each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates ANRO as "Buy" and SAVA as "Buy".
| Metric | ANROAlto Neuroscience… | SAVACassava Sciences,… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $34.60 | — |
| # AnalystsCovering analysts | 8 | 12 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ANRO leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). SAVA leads in 1 (Income & Cash Flow). 2 tied.
Best OverallAlto Neuroscience, Inc. (ANRO)Leads 2 of 6 categories
Loading custom metrics...
ANRO vs SAVA: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ANRO or SAVA a better buy right now?
Analysts rate Alto Neuroscience, Inc.
(ANRO) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ANRO or SAVA?
Over the past 5 years, Alto Neuroscience, Inc.
(ANRO) delivered a total return of +3. 7%, compared to -87. 8% for Cassava Sciences, Inc. (SAVA). Over 10 years, the gap is even starker: ANRO returned +3. 7% versus SAVA's -38. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ANRO or SAVA?
By beta (market sensitivity over 5 years), Cassava Sciences, Inc.
(SAVA) is the lower-risk stock at 1. 92β versus Alto Neuroscience, Inc. 's 2. 60β — meaning ANRO is approximately 35% more volatile than SAVA relative to the S&P 500.
04Which is growing faster — ANRO or SAVA?
On earnings-per-share growth, the picture is similar: Cassava Sciences, Inc.
grew EPS 77. 6% year-over-year, compared to 12. 4% for Alto Neuroscience, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ANRO or SAVA?
Alto Neuroscience, Inc.
(ANRO) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Cassava Sciences, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ANRO leads at 0. 0% versus 0. 0% for SAVA. At the gross margin level — before operating expenses — ANRO leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ANRO or SAVA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ANRO or SAVA better for a retirement portfolio?
For long-horizon retirement investors, Cassava Sciences, Inc.
(SAVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Alto Neuroscience, Inc. (ANRO) carries a higher beta of 2. 60 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SAVA: -38. 0%, ANRO: +3. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ANRO and SAVA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.